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ABSTRACT
A point-prevalence study, performed in 2002 in 143 Spanish hospitals, collected 439 isolates of
Staphylococcus aureus. Of these, 134 (30.5%) were resistant to methicillin (i.e., MRSA). Susceptibility
testing was performed by a microdilution method, and mecA was detected by PCR. The isolates were
characterised by phage typing, pulsed-ﬁeld gel electrophoresis (PFGE) after SmaI digestion, and SCCmec
typing. The 134 MRSA isolates showed resistance to ciproﬂoxacin (93.3%), tobramycin (88.8%),
erythromycin (67.9%), clindamycin (59.7%), gentamicin (42.5%), mupirocin (17.9%), rifampicin (5.2%)
and trimethoprim–sulphamethoxazole (5.2%). All of the isolates were susceptible to glycopeptides.
Twenty-ﬁve resistance patterns were found, of which four accounted for 66% of the isolates. Phage
group III was the most frequent (41.1%). PFGE revealed 31 different patterns, with ten major clones
(including two predominant clones with variable antibiotypes that accounted for 43.3% of the MRSA
isolates) and 21 sporadic patterns. Two isolates belonged to two variants of the Iberian clone (ST247-
MRSA-I), one to the Brazilian clone (ST239-MRSA-III), and seven to the EMRSA-16 clone (ST36-MRSA-
II). SCCmecIV accounted for 70.2% of the isolates (73.9% were type IVA), while SCCmecI, SCCmecII and
SCCmecIII accounted for 22.1%, 6.9% and 0.8% of isolates, respectively, with three non-typeable
isolates. Isolates of SCCmecIV and SCCmecIVA were predominantly nosocomial (95.8% and 97.1%,
respectively). None of the isolates produced Panton–Valentine leukocidin. Thus, two clones carrying
SCCmecIV and SCCmecIVA, respectively, were predominant among nosocomial MRSA isolates
throughout Spain.
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INTRODUCTION
The ﬁrst report of methicillin-resistant Staphylo-
coccus aureus (MRSA) was from the UK in 1961 [1],
soon after the introduction of methicillin as a
therapeutic agent in medical practice. Later, it was
reported that the mecA gene, encoding an altered
penicillin-binding protein (PBP2a or PBP2¢), was
responsible for this resistance. Soon after, MRSA
isolates were recovered from other European
countries, and later from Japan, Australia and
the USA. The SENTRY and the EARSS studies
[2–5] have both demonstrated an increase in
antimicrobial resistance among S. aureus isolates
during subsequent decades and, today, MRSA
strains are disseminated throughout most Euro-
pean countries [6–11] and worldwide [5,12–16].
MRSA is an endemic problem in hospitals [17–19]
and is being recovered increasingly from nursing
homes and the community [20–22]. In Spain,
MRSA was not an epidemiological problem until
the 1980s. In 1981, Trallero et al. [23] reported the
ﬁrst outbreak of MRSA infections in the north of
Spain, and this was followed by reports of several
other outbreaks throughout the country. This
situation deteriorated during the 1990s [24,25], so
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that the prevalence of MRSA in Spain was repor-
ted to be 31.2% in 2002 [26], although conﬁrmation
of the presence of mecA subsequently reduced this
ﬁgure to 30.5%.
The aims of the present study were to analyse
the MRSA isolates obtained during a multicentre
point-prevalence study in Spain in order to
identify the circulating MRSA clones and their
antibiotic resistance patterns, and to determine
the genetic relationships of MRSA isolates from
different geographical areas.
MATERIALS AND METHODS
Bacterial isolates
A point-prevalence study involving 143 Spanish hospitals on a
single day during 2002 yielded a total of 439 clinical isolates of
S. aureus. Full details of the study design and identiﬁcation of
the isolates have been described previously [26]. Of the total
isolates, 134 were MRSA; these were from blood (9.7%), urine
(9.7%), abscesses and wounds (42.5%), catheter tips (6.7%),
the lower respiratory tract (15.7%), soft-tissues (11.2%), sterile
ﬂuids (1.5%) and other sites (3.0%). The isolates were
considered to be community-acquired if a positive culture
was obtained within 48 h of admission, and nosocomial if a
positive culture was obtained thereafter.
Susceptibility testing
Antimicrobial susceptibility testing was performed using the
MicroScan automated broth microdilution method and the Pos
Combo 1S panel (Dade Behring, Sacramento, CA, USA)
following the manufacturer’s guidelines. The antimicrobial
agents tested were penicillin, ampicillin, oxacillin, erythromy-
cin, clindamycin, gentamicin, tobramycin, ciproﬂoxacin, rif-
ampicin, trimethoprim–sulphamethoxazole, vancomycin and
teicoplanin. Susceptibility to mupirocin was determined by the
disk-diffusion method. Inducible clindamycin resistance (using
a disk approximation test) and MIC breakpoints were deter-
mined following CLSI recommendations [27]. Breakpoints for
mupirocin were determined according to MENSURA criteria
[28]. ThemecA gene was detected by PCR as described by Geha
et al. [29].
Phage typing
Phage typing was performed according to Blair and Williams
[30], using the group of 23 phages from the Basic International
Set of Typing Phages. All phages were used at routine test
dilution and 100 · routine test dilution. Interpretation was
based on lysis by at least two different phages [31,32]. The
Speciﬁc Set of Typing Phages for MRSA was also used [33].
Pulsed-ﬁeld gel electrophoresis (PFGE)
All 134 MRSA isolates were genotyped by PFGE following
SmaI digestion of chromosomal DNA, prepared using a
modiﬁcation of the protocol described by Goering and Winters
[34]. The resulting agarose plugs were loaded on agarose 1.2%
w ⁄v gels, and PFGE was performed in a CHEF-DRII apparatus
(Bio-Rad, Hemel Hempstead, UK) in 0.5 · TBE buffer (1 · TBE
is 89 mM Tris, 89 mM boric acid, 1 mM EDTA), with a ramped
pulse time of 1–80 s, and 6 V ⁄ cm for 30 h at 12–14C. The gels
were stained with ethidium bromide, visualised under UV
illumination and photographed. Following analysis according
to the criteria of Tenover et al. [35], a dendrogram was
constructed with Molecular Analyst Software (Bio-Rad) using
the Dice correlation coefﬁcient [36] and the unweighted pair-
group method with averages (UPGMA), with a tolerance position
of 0.8%. According to a previous study [16], each PFGE type
was designated with the letter E, followed by a number that
correlated with the date of isolation, while each subtype was
designated by the letter of the main pulsotype to which it was
closest. Sporadic strains were assigned a number. In a previous
study [16], PFGE type E1 corresponded to ST247-MRSA-I,
types E3 and E10 corresponded to ST146-MRSA-IV, types E6,
E15 and E17 corresponded to ST228-MRSA-I, types E7, E8 and
E11 corresponded to ST125-MRSA-IV, and type E12 corres-
ponded to ST36-MRSA-II.
Multiplex PCR SCCmec typing
SCCmec types were determined using a multiplex PCR
strategy that generated a speciﬁc ampliﬁcation pattern for
each SCCmec structural type [37]. This method does not
identify the ccrAB alleles, but an excellent correlation has been
demonstrated between the full characterisation of SCCmec and
this strategy [37]. Additional typing of isolates that were non-
typeable by this method was performed as described by Zhang
et al. [38].
Detection of Panton–Valentine leukocidin (PVL) genes
The PVL genes (lukS-PV and lukF-PV) were detected by PCR as
described by Lina et al. [39]. S. aureus ATCC 49775 (a PVL-
positive strain) was used as a positive ampliﬁcation control.
RESULTS
Resistance patterns
Of the 134 MRSA isolates studied, 93.3% were
resistant to ciproﬂoxacin, 88.8% to tobramycin,
67.9% to erythromycin, 59.7% to clindamycin,
42.5% to gentamicin, 17.9% tomupirocin (75.0% of
these with high-level resistance, i.e., an MIC
>128 mg ⁄L), 5.2% to rifampicin, and 5.2% to
trimethoprim–sulphamethoxazole. All the isolates
were susceptible to vancomycin (MIC £2 mg ⁄L)
and teicoplanin (MIC £2 mg ⁄L). Among the iso-
lates resistant to erythromycin and clindamycin,
resistance was constitutive in 61 (67.0%) isolates,
inducible in 11 (12.1%) isolates, and showed the
M-phenotype (resistance to erythromycin but sus-
ceptibility to clindamycin) [27] in 19 (20.9%)
isolates. Twenty-ﬁve different resistance patterns
were found, of which four accounted for 66% of
the isolates: resistance to erythromycin, clindamy-
cin, gentamicin, tobramycin and ciproﬂoxacin
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(23.9%); resistance to tobramycin and ciproﬂoxa-
cin (17.9%); resistance to erythromycin, clindamy-
cin, tobramycin and ciproﬂoxacin (15.7%); and
resistance to erythromycin, tobramycin and cipro-
ﬂoxacin (8.2%).
Phage typing
Of the 134 MRSA isolates, 41.1% belonged to
phage group III, 13.4% belonged to phage group
I, 5.2% belonged to mixed phage groups I–III,
6.7% were lysed by phage 95, 3.7% were lysed by
phage 81, and 0.8% belonged to phage group II.
The remaining 29.1% were non-typeable. None of
the strains was lysed by phage group V. Analysis
using the Speciﬁc Set of Typing Phages for MRSA
revealed that 33.6% were lysed by phage 622,
16.4% were lysed by phage M3, 23.1% presented
other patterns, and 26.9% were non-typeable.
PFGE
Genotyping by PFGE revealed 31 different pat-
terns, with 108 (80.6%) isolates belonging to the
ten most common PFGE types (major clones
containing three ormore isolates) present through-
out Spain, and 26 (19.4%) isolates belonging to 21
sporadic clones. The major clones were E-1, E-3,
E-6, E-7, E-8, E-10, E-11, E-12, E-15 and E-17
(Table 1). Clones E-7 (with subtypes E-7a, E-7b and
E7c; 26.1%) and E-8 (subtypes E-8a and E-8b;
17.2%) predominated, and together accounted for
43.3% of the isolates. Two isolates (E-1c and E-1d)
belonged to two different variants of the Iberian
clone (ST247-MRSA-I) and these were susceptible
only to rifampicin, trimethoprim–sulphameth-
oxazole and glycopeptides. One isolate belonged
to the Brazilian clone (ST239-MRSA-III), and was
resistant to all antimicrobial agents tested, with the
exception of the glycopeptides.
The antimicrobial resistance of the predomin-
ant, major and sporadic clones was highly
variable. Fourteen different resistance patterns
were found among isolates belonging to the two
predominant clones, and 62.1% of these isolates
were susceptible to gentamicin and resistant to
tobramycin. The distribution of the most fre-
quent resistance patterns among the different
genotypes is shown in Table 2. The international
clone EMRSA-16 (ST36-MRSA-II) was represent-
ed by seven (5.2%) isolates with three different
resistance patterns. Isolates belonging to this
clone were obtained from four different institu-
tions in northern and central Spain. Clone E-8
(ST125-MRSA-IV) included mainly isolates of
phage group III, clone E-7 (ST125-MRSA-IV)
included non-typeable isolates, clone E-3
(ST146-MRSA-IV) included isolates lysed by
phage group 95, and the sporadic clones inclu-
ded all the phage groups.
SCCmec
The distribution of the different SCCmec types
among the different clones is shown in Table 1.
SCCmecIV accounted for 68.7% of the isolates,
with 73.9% of these carrying SCCmecIVA. This
Table 1. Distribution of pulsed-ﬁeld gel electrophoresis
(PFGE) proﬁles and SCCmec types among 134 isolates of
methicillin-resistant Staphylococcus aureus from Spain
PFGE proﬁles
No. of
isolates (%)
SCCmec
type Total (%)
E-1 2 (1.5) I 29 (21.6)
E-6 11 (8.2)
E-15 3 (2.2)
E-17 5 (3.7)
SP 8 (6.0)
E-12 7 (5.2) II 9 (6.7)
SP 2 (1.5)
SP 1 (0.8) III 1 (0.8)
E-3 9 (6.7) IV 92 (68.7)
E-7a 35 (26.1)
E-8a 23 (17.2)
E-10 3 (2.2)
E-11 10 (7.5)
SP 12 (9.0)
ND 3 (2.2) 3 (2.2)
Total (%) 134 (100) 134 (100)
aE-7 and E-8, predominant clones.
SP, sporadic cases; ND, not determined.
Table 2. Distribution of resistance patterns among the
different clones of methicillin-resistant Staphylococcus
aureus from Spain
Resistance patternsa
No. of isolates (% resistance)
Predominant
clones (n = 2)b
Major
clones (n = 8)c
Sporadic
clones (n = 21)
RP1 9 (15.5) 9 (18.0) 3 (11.5)
RP2 9 (15.5) 2 (4.0) 0
RP3 5 (8.6) 21 (42.0) 6 (23.1)
RP4 14 (24.1) 7 (14.0) 3 (11.5)
Others 21 (36.3) 11 (22.0) 14 (53.9)
Total 58 (100) 50 (100) 26 (100)
aRP1, erythromycin, clindamycin, tobramycin, ciproﬂoxacin; RP2, erythromycin,
tobramycin, ciproﬂoxacin; RP3, erythromycin, clindamycin, gentamicin, tobramy-
cin, ciproﬂoxacin; RP4, tobramycin, ciproﬂoxacin.
bE-7 and E-8.
cE-1, E-3, E-6, E-10, E-11, E-12, E-15 and E-17.
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type included ﬁve major clones (E-3, E-7, E-8, E-10
and E-11) and nine sporadic clones.
SCCmecI accounted for 21.6% of the isolates,
including those in four major clones (E-1, E-6, E15
and E-17) and six sporadic clones. SCCmecII and
SCCmecIII were less frequent (6.7% and 0.8%,
respectively). Three strains were non-typeable
using this scheme, but further characterisation
identiﬁed one isolate as type IVC, and conﬁrmed
that the remaining two isolates did not belong to
type V [38]. The only SCCmecIII isolate (subtype
IIIA) belonged to ST239-MRSA-III (Brazilian
clone). The two isolates belonging to variants of
ST247-MRSA-I (Iberian clone) carried SCCmecI
and SCCmecIA, respectively. All isolates belong-
ing to ST36-MRSA-II (international clone EMRSA-
16) carried SCCmecII. The correlation between the
most frequent resistance patterns and SCCmec
types is shown in Table 3. The majority (62.0%) of
the isolates with SCCmecIV were susceptible to
gentamicin and resistant to tobramycin.
Correlation of acquisition with SCCmec type
As indicated above, isolates were distributed by
acquisition (community ⁄nosocomial) using only
the scarce epidemiological data provided by the
participating institutions. Of the 134 MRSA iso-
lates, 127 were nosocomial and seven were clas-
siﬁed as community-acquired (i.e., isolated from
patients within 48 h of admission). All MRSA
isolates with SCCmecI (29 isolates) and SCCmecIII
(one isolate) were nosocomial. Eight (88.9%)
isolates with SCCmecII were nosocomial, and
acquisition was predominantly nosocomial for
isolates with SCCmecIV (95.8%) or SCCmecIVA
(97.1%). Only three isolates with SCCmecIV or
SCCmecIVA were acquired in the community. The
three non-typeable isolates were also acquired in
the community.
Detection of PVL genes
All 134 MRSA isolates tested were PVL-negative.
DISCUSSION
MRSA is a nosocomial pathogen associated with
increased morbidity and mortality, and commu-
nity-acquired MRSA infections appear to be an
emerging phenomenon in many countries. A
recent point-prevalence study in Spain revealed
that 30.5% of S. aureus isolates were MRSA [26].
The present study revealed that the 134 MRSA
isolates comprised 31 different PFGE patterns,
with two predominant clones. In 1989, the so-
called Iberian clone of MRSA was responsible for
an epidemic in Spain [24,25,40], but only two of
the 134 MRSA isolates in the present study
belonged (two different variants) to the Iberian
clone (ST247-MRSA-I). This observation concurs
with other studies that have demonstrated a
decrease in the incidence of the Iberian clone in
many healthcare institutions in Europe [8,41]. The
UK EMRSA-16 clone (ST36-MRSA-II) has recently
been identiﬁed in a number of other European
countries [42] and has been reported to be a major
clone in a Spanish hospital [43], but accounted for
only 5.2% of the isolates in the present study,
which is in agreement with a previous study
which found that this clone was scarce in Spain
[16]. The EMRSA-15 clone (ST22-MRSA-IV),
which is epidemic in hospitals in many European
countries [44], was not found in the present study.
In 1989, the predominant (93.2%) resistance
pattern found in MRSA in Spain involved resis-
tance to ciproﬂoxacin, erythromycin, clindamycin,
gentamicin, tobramycin and rifampicin [25]. The
present study found 25 different resistance
patterns, of which the most frequent was suscep-
tibility to rifampicin, trimethoprim–sulphameth-
oxazole and gentamicin, variable resistance to
clindamycin, and resistance to tobramycin and
ciproﬂoxacin. Resistance to tobramycin and sus-
ceptibility to gentamicin is probably caused by the
presence of the ant4¢ gene, which confers resist-
ance to kanamycin, tobramycin and amikacin.
This phenotype occurs at a high frequency in
France [45]. The predominant and major geno-
types showed variable resistance patterns
Table 3. Correlation between resistance patterns and
SCCmec type
Resistance patternsb
SCCmec type, n (%)a
I IA II IIIA IV IVA
RP1 0 0 5 (55.6) 0 0 15 (22.0)
RP2 0 0 1 (11.1) 0 0 10 (14.7)
RP3 21 (77.8) 2 1 (11.1) 0 3 (12.5) 5 (7.4)
RP4 0 0 0 0 2 (8.3) 22 (32.4)
Others 6 (22.2) 0 2 (22.2) 1 (100) 19 (79.2) 16 (23.5)
Total 27 (100) 2 (100) 9 (100) 1 (100) 24 (100) 68 (100)
aTwo isolates that were non-typeable using this scheme are excluded from this
table.
bRP1, erythromycin, clindamycin, tobramycin, ciproﬂoxacin; RP2, erythromycin,
tobramycin, ciproﬂoxacin; RP3, erythromycin, clindamycin, gentamicin, tobramy-
cin, ciproﬂoxacin; RP4, tobramycin, ciproﬂoxacin.
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(Table 2), although there was a trend towards
more susceptible strains in comparison with a
previous study [26]. The majority (66%) of the
isolates exhibited one of four different antibiotic
resistance patterns, none of which included glyco-
peptide resistance.
Phage group III predominated among the
isolates (41.1%), followed by non-typeable iso-
lates (29.1%). This is in agreement with results
from other European countries; thus, in a pan-
European surveillance study [11], 76% of isolates
belonged to phage group III, while 13% of isolates
were non-typeable. The high percentage of non-
typeable strains in the present study may indicate
that the MRSA population is a mixture of epi-
demic and non-epidemic strains.
The most frequent SCCmec type found was
SCCmecIV, which was present in 68.7% of iso-
lates, in three of the major clones, and in the two
predominant clones. The antimicrobial resistance
patterns of these isolates varied considerably.
Initially, SCCmecIV was associated with commu-
nity-acquired MRSA, although it is currently one
of the most frequent nosocomial SCCmec types
found in several countries [46]. According to the
epidemiological data provided by the particip-
ating institutions in the present study, only three
of the 92 isolates with SCCmecIV were community-
acquired.
It is important to note that isolates belonging to
sporadic clones carried SCCmecI and SCCmecIV.
The possible spread of multiresistant SCCmecI
isolates is indicative of a need to maintain a high
level of surveillance in order to control dissemin-
ation of these organisms. Only nine (6.7%) iso-
lates carried SCCmecII, of which eight were
nosocomial. Seven belonged to the EMRSA-16
clone (ST36-MRSA-II) and, in accordance with
previous studies, these isolates had a multiresis-
tant phenotype, but were susceptible to gentam-
icin [44]. Finally, the only isolate (0.8%) with
SSCmecIII, belonging to the Brazilian clone
(ST239-MRSA-III), was resistant to macrolides,
clindamycin, aminoglycosides, ciproﬂoxacin, rif-
ampicin and trimethoprim–sulphamethoxazole.
Although the majority of MRSA isolates car-
ried SCCmecIV and SCCmecIVA, none produced
the PVL toxin. This ﬁnding is not surprising,
since there were only seven possible community-
acquired MRSA isolates in the study. Neverthe-
less, it is unusual for isolates considered to
be community-acquired to be PVL-negative.
However, as indicated above, the limited infor-
mation provided by the participating hospitals
made it difﬁcult to perform an adequate evalu-
ation of the mode of acquisition; it is not clear
whether the patients involved were hospital-
ised previously and whether these seven PVL-
negative isolates were genuine community
acquisitions.
In conclusion, two predominant clones carrying
SCCmecIV and SCCmecIVA were identiﬁed in
nosocomial MRSA isolates throughout Spain.
These clones have replaced the Iberian clone
(ST247-MRSA-I) and show variable patterns of
resistance to antimicrobial agents, but remain
susceptible to glycopeptides. Although the phen-
otypic expression of antimicrobial resistance var-
ied considerably, 66% of the isolates showed one
of four major antibiotic resistance patterns, the
most frequent of which was susceptibility to
gentamicin and resistance to tobramycin.
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